PlainPharmaWatch

CMS Open Payments · Program Year 2024

Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc. reported $337,131.84 across General Payments, Research, and Ownership to 658 physicians and teaching hospitals across 658 transactions.

See the rankings → How this is sourced
$337.1K
All-tracks total
658
Transactions
658
Recipients
+$159.8K
General Payments vs PY2023

Noven Pharmaceuticals, Inc. reported $337,131.84 across all CMS Open Payments tracks (General + Research + Ownership) to 658 physicians and teaching hospitals in Program Year 2024 - ranking #866 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $337,131.84, averaging $512.36 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer noven-pharmaceuticals-inc Noven Pharmaceuticals, Inc.

$337.1K · #866/1,925 · 0.0% industry · PY2024

  • TOT $337.1K
  • RANK #866
  • SHARE 0.0%
  • TXN 658
  • RCP 658
  • CAT 4
  • GEN $337.1K
  • ΔGEN +$159.8K
  • TOP1 11.9%
  • PY 2024

Volume peers

Nearest volume peer: HemoSonics LLC ($336.6K)

ALK-Abello, Inc$339.4KUCB Biosciences Inc.$337.8KNoven Pharmaceuticals, Inc. …$337.1KHemoSonics LLC$336.6KIntuitive Surgical Operation…$335.6K
All-tracks payment totals near Noven Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Noven Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Noven Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $159.8K (+90.1%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: NOVEN PHARMACEUTICALS, INC.PY2023: NOVEN PHARMACEUTICALS, INC.PY2024: Noven Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$177.4KPY2024$337.1K
PY2023
$177,368.68
PY2024
$337,131.84

What the Data Shows for Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc. ranks #866 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $337,131.84 across 658 transactions to 658 physicians and teaching hospitals - $512.36 per transaction and $512.36 per recipient on average.

The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Faculty or Speaker (Medical Education)" at $266.9K, accounting for 79.2% of this company's General Payments and 151 transactions.

General Payment Breakdown by Type

Across 4 types of general payments, Noven Pharmaceuticals, Inc.'s largest category was "Compensation for Faculty or Speaker (Medical Education)" at $266.9K - 79.2% of General Payments.

Noven Pharmaceuticals, Inc. reports 4 general-payment categories - the top three are Compensation for Faculty or Speaker (Medical Education) (79.2%), Food and Beverage (9.4%), and Travel and Lodging (7.3%). The remaining 1 category make up 4.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Noven Pharmaceuticals, Inc. divides its payments

General-payment categories, ordered by reported total

1. Compensation for Faculty …$266.9K2. Food and Beverage$31.6K3. Travel and Lodging$24.7K4. Consulting Fee$13.9K
Payment Type Amount Transactions
Compensation for Faculty or Speaker (Medical Education) $266.9K 151
Food and Beverage $31.6K 432
Travel and Lodging $24.7K 65
Consulting Fee $13.9K 10

Recipient Concentration in General Payments

The five largest recipient relationships account for $128,599.54 (38.1%) of $337,131.84 in this company's General Payments records across 401 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Noven Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Michelle Holloway$40.0KBirgit Amann$29.3KGregory Mattingley$21.7KNapoleon Higgins$20.0KAndrew Cutler$17.6K
  1. 1

    Michelle Holloway

    $39,975.57 across 37 reported transactions

  2. 2

    Birgit Amann

    $29,277.92 across 24 reported transactions

  3. 3

    Gregory Mattingley

    $21,678.13 across 16 reported transactions

  4. 4

    Napoleon Higgins

    $20,020.37 across 19 reported transactions

  5. 5

    Andrew Cutler

    $17,647.55 across 12 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Noven Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Noven Pharmaceuticals, Inc..

Shoulder Innovations, Inc.

HHI 471

Canon Medical Systems USA, Inc.

HHI 477

Sage Therapeutics, Inc.

HHI 470

IsoRay, Inc

HHI 469

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Noven Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Noven Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.